前列腺癌图像引导中度大分割质子治疗十年结局
基于单中心前瞻性登记研究,报告582例低危和中危前列腺癌患者接受双散射中度大分割质子治疗(低危70.0 GyRBE,2.5 GyRBE/次;中危72.5 GyRBE)的十年结局。中位随访10.2年,总体无疾病进展生存率91.9%,低危95.9%,中危88.4%;局部复发率3.6%,≥4级胃肠或泌尿毒性未发生。
要点
- 低危与中危前列腺癌质子治疗后十年无进展生存率分别为95.9%和88.4%。
- 10年≥3级胃肠毒性和≥3级泌尿毒性累积发生率分别为1.4%和2.7%。
- 第二恶性肿瘤总体发生率7.2%,野内和/或盆腔内癌仅1.7%。
核心结论
- 中位随访超过十年,中度大分割质子治疗显示出持久的高疗效、医生评估毒性极低及第二恶性肿瘤比例低。
- 中危患者疾病控制率优异但略低,可能反映该时期雄激素剥夺治疗的保守使用。
研究设计与样本
- 单机构经IRB批准的前瞻性结局登记研究,2008年至2015年纳入582例前列腺癌患者。
主要发现
- 中位随访10.2年(范围1.0-15.1年),总体无疾病进展生存率91.9%,低危95.9%,中危88.4%。
- 有利中危和不利中危亚组无疾病进展生存率分别为94.0%和82.7%。
- 局部复发率3.6%;10年2级胃肠毒性累积发生率12.0%,3级胃肠毒性1.4%,3级泌尿毒性2.7%。
- 未发生≥4级胃肠或泌尿毒性;第二恶性肿瘤总体7.2%,排除非黑色素瘤皮肤癌后4.6%,质子治疗后超过5年发生者2.9%,野内和/或盆腔内癌1.7%。
临床怎么用
- 对于低危和有利中危前列腺癌,图像引导中度大分割质子治疗可作为有效且毒性低的放疗选择。
- 不利中危患者疾病控制率略低,需关注雄激素剥夺治疗的使用策略。
- 长期随访中第二恶性肿瘤发生率低,尤其是野内和/或盆腔内癌。
局限性
- 单中心前瞻性登记研究,非随机对照设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report 10-year outcomes after image-guided moderately hypofractionated proton therapy for prostate cancer. MATERIALS AND METHODS: Using an IRB-approved, single institutional prospective outcomes registry at our institution between 2008 and 2015, we updated the previously reported outcomes results of 582 prostate cancer patients treated with double-scattered moderately hypofractionated proton therapy. Two hundred and seventy-one patients had low-risk, and 311 had intermediate-risk disease, including 148 with favorable intermediate-risk and 163 with unfavorable-intermediate-risk. The compressed course of proton therapy consisted of 70.0 GyRBE (2.5 GyRBE/fraction) for low-risk and 72.5 GyRBE for intermediate-risk patients. Seventeen patients received androgen deprivation therapy for a median six months. RESULTS: Median follow-up was 10.2 years (range, 1.0-15.1). Freedom from disease progression overall and in low-risk and intermediate-risk subsets were 91.9%, 95.9%, and 88.4%, respectively. Favorable intermediate-risk and unfavorable-intermediate-risk subsets were 94.0% and 82.7%, respectively. Local recurrence occurred in 3.6% of patients. The cumulative incidences of 10-year grade 2 gastrointestinal, grade 3 gastrointestinal, and grade 3 genitourinary toxicities were 12.0%, 1.4%, and 2.7%, respectively. No grade ≥ 4 gastrointestinal or genitourinary toxicities occurred. The proportion of patients developing second malignancies is 7.2% overall, 4.6% with the exclusion of non-melanomatous skin cancers, 2.9% for cancers developing more than five years after proton therapy, and only 1.7% for in-field and/or pelvic cancers. CONCLUSION: With a median follow-up over ten years, this report establishes the durability of excellent outcomes with moderately hypofractionated proton therapy including high efficacy, minimal physician-assessed toxicity, excellent patient-reported outcomes, and a low proportion of patients developing second malignancies. The excellent but slightly lower rate of disease control in intermediate risk patients may reflect the conservative use of androgen deprivation therapy during this time frame.
引用
- Henderson RH, Bryant CM, Nichols RC, et al. Ten-year outcomes for image-guided moderately hypofractionated proton therapy for prostate cancer. Radiother Oncol. 2026. PMID: 41806873. doi:10.1016/j.radonc.2026.111482
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。